Heranova – Lifesciences

product pipeline

Our women’s health product pipeline is focused on providing non-invasive and minimally invasive, non-antibiotic, non-hormonal solutions to guide personalized treatment for endometriosis and infertility. This integrated and focused approach will allow us to swiftly provide valuable solutions to women and their physicians.

Endometriosis

HerResolveTM
Diagnostic test for endometriosis

Launched

First-in-class blood-based diagnostic test. Endometriosis is a highly debilitating disease impacting 10% of reproductive-age women, but the current gold standard for confirming diagnosis is laparoscopic surgery, which can often result in mis- or late diagnosis.4

Female fertility

HerReceptivityTM
Endometrial receptivity test

Clinical

HerReceptivity™ is an NGS-based test to identify each patient’s optimal embryo transplantation time during the IVF process. The average success rate of IVF procedures is currently only ~50% for women under 35 using their own eggs5, and 10% of patients experience recurrent implantation failure caused by repeated IVF failure.6

HerBiotaTM
Uterine microbiome test

Clinical

HerBiota™ is an NGS-based test to assess the uterine microbiome environment. It can detect chronic endometritis, and other GYN conditions due to pathogens and/or dysbiosis as well as help clinicians provide personalized treatment recommendations.
HerBiotaTM - Complete
Uterine/vaginal microbiome test 

Clinical

HerBiota™-Complete is an NGS-based test to assess both the uterine and vaginal microbiome environment to help clinicians provide personalized treatment recommendations.

HerTempoTM
Ovarian reserve test

Clinical

HerTempo™ is a proprietary algorithmic-based ovarian reserve assessment for estimating a woman’s remaining childbearing years based on patient-specific clinical information.

indication

PRODUCT

 DESCRIPTION

pre-clinical

clinical

launched

Endometriosis

HerResolveTM

First-in-class blood-based diagnostic test. Endometriosis is a highly debilitating disease impacting 10% of reproductive-age women, but the current gold standard for confirming diagnosis is laparoscopic surgery, which can often result in mis- or late diagnosis.4

Diagnostic test for endometriosis

Female fertility

HerReceptivityTM

HerReceptivity™ is an NGS-based test to identify each patient’s optimal embryo transplantation time during the IVF process. The average success rate of IVF procedures is currently only ~50% for women under 35 using their own eggs5, and 10% of patients experience recurrent implantation failure caused by repeated IVF failure.6

Endometrial receptivity test

HerBiotaTM

HerBiota™ is an NGS-based test to assess the uterine microbiome environment. It can detect chronic endometritis, and other GYN conditions due to pathogens and/or dysbiosis as well as help clinicians provide personalized treatment recommendations.

Uterine microbiome test

HerBiotaTM
- Complete

HerBiota™-Complete is an NGS-based test to assess both the uterine and vaginal microbiome environment to help clinicians provide personalized treatment recommendations.

Uterine/vaginal microbiome test 

HerTempoTM

HerTempo™ is a proprietary algorithmic-based ovarian reserve assessment for estimating a woman’s remaining childbearing years based on patient-specific clinical information.

Ovarian reserve test